Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 270

1.

Patient-Reported Outcomes in a Phase 2 Study Comparing Atezolizumab Alone or With Bevacizumab Versus Sunitinib in Previously Untreated Metastatic Renal Cell Carcinoma.

Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Suarez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis E, Powles T.

BJU Int. 2020 Mar 31. doi: 10.1111/bju.15058. [Epub ahead of print]

PMID:
32233107
2.

[SARS-CoV-2/COVID 19 Infection and Solid Cancers: Synthesis of Recommendations for Health Professionals].

Grellety T, Ravaud A, Canivet A, Ganem G, Guimbaud R, Kaluzinski L, Krakowski I, Mayeur D, Lotz JP, You B.

Bull Cancer. 2020 Mar 27. pii: S0007-4551(20)30152-1. doi: 10.1016/j.bulcan.2020.03.001. [Epub ahead of print] French. No abstract available.

PMID:
32229048
3.

Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.

Rolfo C, Isambert N, Italiano A, Molife LR, Schellens JHM, Blay JY, Decaens T, Kristeleit R, Rosmorduc O, Demlova R, Lee MA, Ravaud A, Kopeckova K, Learoyd M, Bannister W, Locker G, de Vos-Geelen J.

Br J Clin Pharmacol. 2020 Mar 29. doi: 10.1111/bcp.14283. [Epub ahead of print]

PMID:
32227355
4.

The official French guidelines to protect patients with cancer against SARS-CoV-2 infection.

You B, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R, Kaluzinski L, Krakowski I, Mayeur D, Grellety T, Lotz JP.

Lancet Oncol. 2020 Mar 25. pii: S1470-2045(20)30204-7. doi: 10.1016/S1470-2045(20)30204-7. [Epub ahead of print] No abstract available.

PMID:
32220659
5.

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.

Negrier S, Rioux-Leclercq N, Ferlay C, Gross-Goupil M, Gravis G, Geoffrois L, Chevreau C, Boyle H, Rolland F, Blanc E, Ravaud A, Dermeche S, Flechon A, Albiges L, Pérol D, Escudier B; GETUG collaborative group.

Eur J Cancer. 2020 Apr;129:107-116. doi: 10.1016/j.ejca.2020.02.001. Epub 2020 Mar 5.

PMID:
32146304
6.

Prognostic factors for cancer patient admitted to a medical intensive care unit.

Baylot C, Francopoulo A, Gross-Goupil M, Quivy A, Guisset O, Hilbert G, Frison E, Ravaud A, Daste A.

Acta Oncol. 2020 Apr;59(4):458-461. doi: 10.1080/0284186X.2019.1711171. Epub 2020 Jan 16. No abstract available.

PMID:
31948319
7.

The development of a regional referral pathway for locally recurrent rectal cancer: A Delphi consensus study.

Denost Q, Bousser V, Morin-Porchet C, Vincent C, Pinon E, Collin F, Martin A, Colombani F, Digue L, Ravaud A, Harji DP, Saillour-Glénisson F.

Eur J Surg Oncol. 2020 Mar;46(3):470-475. doi: 10.1016/j.ejso.2019.12.001. Epub 2019 Dec 2.

PMID:
31866109
8.

Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience.

Gonnet A, Salabert L, Roubaud G, Catena V, Brouste V, Buy X, Gross Goupil M, Ravaud A, Palussière J.

BMC Cancer. 2019 Dec 3;19(1):1182. doi: 10.1186/s12885-019-6345-2.

9.

Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.

Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P, Ravaud A, Durán I, Szabados B, Castellano D, Giannatempo P, Loriot Y, Carles J, Anguera Palacios G, Lefort F, Raggi D, Gross Goupil M, Powles T, Van der Heijden MS.

Eur Urol. 2020 Feb;77(2):269-276. doi: 10.1016/j.eururo.2019.10.004. Epub 2019 Nov 5.

PMID:
31699525
10.

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D.

Nat Med. 2019 Nov;25(11):1706-1714. doi: 10.1038/s41591-019-0628-7. Epub 2019 Nov 4.

PMID:
31686036
11.

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.

Vaishampayan U, Schöffski P, Ravaud A, Borel C, Peguero J, Chaves J, Morris JC, Kotecki N, Smakal M, Zhou D, Guenther S, Bajars M, Gulley JL.

J Immunother Cancer. 2019 Oct 24;7(1):275. doi: 10.1186/s40425-019-0746-2.

12.

Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

Bersanelli M, Iacovelli R, Buti S, Houede N, Laguerre B, Procopio G, Lheureux S, Fischer R, Negrier S, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C.

Eur Urol Oncol. 2019 Jul 19. pii: S2588-9311(19)30099-9. doi: 10.1016/j.euo.2019.06.018. [Epub ahead of print]

PMID:
31331862
13.

EPOCK study protocol: a mixed-methods research program evaluating cancer care coordination nursing occupations in France as a complex intervention.

Colombani F, Sibé M, Kret M, Quintard B, Ravaud A, Saillour-Glénisson F.

BMC Health Serv Res. 2019 Jul 12;19(1):483. doi: 10.1186/s12913-019-4307-7.

14.

Which place for avelumab in the management of urothelial carcinoma?

Larroquette M, Gross-Goupil M, Daste A, Robert G, Ravaud A, Domblides C.

Expert Opin Biol Ther. 2019 Sep;19(9):863-870. doi: 10.1080/14712598.2019.1637412. Epub 2019 Jul 9.

PMID:
31286802
15.

Long-term prognosis of septic shock in cancer patients.

Camou F, Didier M, Leguay T, Milpied N, Daste A, Ravaud A, Mourissoux G, Guisset O, Issa N.

Support Care Cancer. 2020 Mar;28(3):1325-1333. doi: 10.1007/s00520-019-04937-4. Epub 2019 Jun 26.

PMID:
31243586
16.

Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature.

de Vries-Brilland M, Sionneau B, Dutriaux C, Blay JY, Ravaud A, Gross-Goupil M.

Clin Genitourin Cancer. 2019 Aug;17(4):e721-e723. doi: 10.1016/j.clgc.2019.02.012. Epub 2019 Mar 15. No abstract available.

PMID:
31109800
17.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
18.

The interest of sequential treatment with immune check point inhibitors followed chemotherapy: A case report.

Lasserre M, Domblides C, Gross-Goupil M, Ravaud A, Daste A.

Oral Oncol. 2019 Jul;94:125-127. doi: 10.1016/j.oraloncology.2019.05.001. Epub 2019 May 8. No abstract available.

PMID:
31078371
19.

Asymptomatic stroke is an underestimated side effect of cabozantinib.

Bronnimann C, Sibon I, Ravaud A, Gross-Goupil M.

Rev Neurol (Paris). 2019 Jun;175(6):409-410. doi: 10.1016/j.neurol.2018.10.008. Epub 2019 May 2. No abstract available.

PMID:
31056194
20.

Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.

Rolfo C, de Vos-Geelen J, Isambert N, Molife LR, Schellens JHM, De Grève J, Dirix L, Grundtvig-Sørensen P, Jerusalem G, Leunen K, Mau-Sørensen M, Plummer R, Learoyd M, Bannister W, Fielding A, Ravaud A.

Clin Pharmacokinet. 2019 Sep;58(9):1165-1174. doi: 10.1007/s40262-019-00754-4.

PMID:
30877569
21.

Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.

Kammerer-Jacquet SF, Brunot A, Lefort M, Bayat S, Peyronnet B, Verhoest G, Mathieu R, Lespagnol A, Mosser J, Laguerre B, Ravaud A, Bernhard JC, Dupuis F, Yacoub M, Belaud-Rotureau MA, Bensalah K, Rioux-Leclercq N.

Clin Genitourin Cancer. 2019 Jun;17(3):169-176.e1. doi: 10.1016/j.clgc.2019.01.014. Epub 2019 Feb 4.

22.

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard AC, Delva R, Rolland F, Mouret L, Priou F, Beuzeboc P, Gravis G, Linassier C, Gomez P, Voog E, Muracciole X, Abraham C, Banu E, Ferrero JM, Ravaud A, Krakowski I, Lagrange JL, Deplanque G, Zylberait D, Bozec L, Houede N, Culine S, Elaidi R.

JAMA Oncol. 2019 May 1;5(5):623-632. doi: 10.1001/jamaoncol.2018.6607.

23.

Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case report.

Daste A, Digue L, Ravaud A, Domblides C.

Oral Oncol. 2019 Feb;89:150-152. doi: 10.1016/j.oraloncology.2019.01.002. Epub 2019 Jan 11. No abstract available.

PMID:
30639133
24.

Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.

Gouverneur A, Coutureau J, Jové J, Rouyer M, Grelaud A, Duc S, Gérard S, Smith D, Ravaud A, Droz C, Bernard MA, Lassalle R, Forrier-Réglat A, Noize P; ETNA study group and the EREBUS study group.

Clin Colorectal Cancer. 2019 Mar;18(1):e150-e162. doi: 10.1016/j.clcc.2018.11.005. Epub 2018 Nov 29.

PMID:
30630730
25.

Traitement focal et traitement systémique dans la prise en charge du cancer du rein métastatique : une question de complémentarité.

Salabert L, Sionneau B, Cochin V, Ravaud A, Gross-Goupil M.

Bull Cancer. 2018 Dec;105 Suppl 3:S221-S228. doi: 10.1016/S0007-4551(18)30376-X. French.

PMID:
30595150
26.

Adjuvant therapy after nephrectomy for renal cell carcinoma.

Ravaud A.

Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:33-36. doi: 10.1111/ajco.13056. Review.

PMID:
30489037
27.

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A.

Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329.

28.

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha HS, Patel A, Lechuga M, Ravaud A.

Clin Cancer Res. 2019 Feb 15;25(4):1165-1173. doi: 10.1158/1078-0432.CCR-18-1724. Epub 2018 Nov 6.

29.

Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus.

Larroquette M, Domblides C, Cousin S, De Gabory L, Dupin C, Ravaud A, Daste A.

Oral Oncol. 2018 Dec;87:207-209. doi: 10.1016/j.oraloncology.2018.10.017. Epub 2018 Oct 18. No abstract available.

PMID:
30343985
30.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
31.

A cross-sectional assessment of diabetes self-management, education and support needs of Syrian refugee patients living with diabetes in Bekaa Valley Lebanon.

Elliott JA, Das D, Cavailler P, Schneider F, Shah M, Ravaud A, Lightowler M, Boulle P.

Confl Health. 2018 Sep 12;12:40. doi: 10.1186/s13031-018-0174-9. eCollection 2018.

32.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Nov 15;24(22):5534-5542. doi: 10.1158/1078-0432.CCR-18-1045. Epub 2018 Jul 30.

33.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Dec;24(12):1941.

34.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.

35.

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17.

36.

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.

Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard JC, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero JM, Chamorey E, Blot-Chabaud M, Pagès G.

Theranostics. 2018 Mar 28;8(9):2447-2458. doi: 10.7150/thno.23002. eCollection 2018.

37.

Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy.

Daste A, De-Mones E, Cochin V, Dupin C, Digue L, Ravaud A, Domblides C.

Oral Oncol. 2018 Jun;81:116-118. doi: 10.1016/j.oraloncology.2018.04.013. Epub 2018 Apr 24. No abstract available.

PMID:
29703607
38.

Treatment of spinal metastases in renal cell carcinoma: A critical review.

Teyssonneau D, Gross-Goupil M, Domblides C, Haaser T, Pointillart V, Daste A, Hauger O, Ravaud A.

Crit Rev Oncol Hematol. 2018 May;125:19-29. doi: 10.1016/j.critrevonc.2018.02.017. Epub 2018 Mar 6. Review.

PMID:
29650272
39.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

40.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casey M, Laguerre B, Pandha HS, Pantuck AJ, Patel A, Lechuga MJ, Ravaud A.

Clin Cancer Res. 2018 Apr 1;24(7):1554-1561. doi: 10.1158/1078-0432.CCR-17-2822. Epub 2018 Jan 26.

41.

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A.

Lancet. 2018 Feb 24;391(10122):748-757. doi: 10.1016/S0140-6736(17)33297-X. Epub 2017 Dec 18. Erratum in: Lancet. 2018 Oct 20;392(10156):1402.

PMID:
29268948
42.

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.

Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, Britten CD, Dirix L, Lee KW, Taylor M, Schöffski P, Wang D, Ravaud A, Gelb AB, Xiong J, Rosen G, Gulley JL, Apolo AB.

Lancet Oncol. 2018 Jan;19(1):51-64. doi: 10.1016/S1470-2045(17)30900-2. Epub 2017 Dec 5. Erratum in: Lancet Oncol. 2018 Jul;19(7):e335.

PMID:
29217288
43.

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T; FHU ACRONIM.

Ann Rheum Dis. 2018 Mar;77(3):393-398. doi: 10.1136/annrheumdis-2017-212257. Epub 2017 Nov 16.

PMID:
29146737
45.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
46.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.

Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.

47.

Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.

Ravaud A, Gomez-Roca C, Picat MQ, Digue L, Chevreau C, Gimbert A, Chauzit E, Sitta R, Cornelis F, Asselineau J, Aziza R, Daste A, Quemener C, Baud J, Bikfalvi A, Pedenon-Périchout D, Doussau A, Molimard M, Delord JP.

Eur J Cancer. 2017 Nov;85:39-48. doi: 10.1016/j.ejca.2017.07.031. Epub 2017 Sep 5.

PMID:
28886476
48.

[Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].

Bertolaso P, Leroy L, Gross-Goupil M, Aupee O, Ravaud A, Roubaud G, Cazeau AL, Le Moulec S.

Bull Cancer. 2017 Sep;104(9):762-770. doi: 10.1016/j.bulcan.2017.06.011. Epub 2017 Aug 7. Review. French.

PMID:
28797482
49.

Immune checkpoint inhibitors and elderly people: A review.

Daste A, Domblides C, Gross-Goupil M, Chakiba C, Quivy A, Cochin V, de Mones E, Larmonier N, Soubeyran P, Ravaud A.

Eur J Cancer. 2017 Sep;82:155-166. doi: 10.1016/j.ejca.2017.05.044. Epub 2017 Jul 6. Review.

PMID:
28689093
50.

Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.

Kammerer-Jacquet SF, Brunot A, Bensalah K, Campillo-Gimenez B, Lefort M, Bayat S, Ravaud A, Dupuis F, Yacoub M, Verhoest G, Peyronnet B, Mathieu R, Lespagnol A, Mosser J, Edeline J, Laguerre B, Bernhard JC, Rioux-Leclercq N.

Urol Oncol. 2017 Oct;35(10):603.e7-603.e14. doi: 10.1016/j.urolonc.2017.05.015. Epub 2017 Jun 12.

Supplemental Content

Loading ...
Support Center